This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
Conclusions: We established a novel human GIST xenograft, UZLX-GIST9, harbouring KIT exon 11 and 17 mutations and maintaining the pheno-and genotype of the original tumour. UZLX-GIST9 shows different levels of response to standard TKIs. This model will help to study TKI resistance and to explore novel treatment approaches for patients with TKI-resistant GIST.
Source: Epidemiologic Perspectives and Innovations - August 10, 2014 Category: Epidemiology Authors: Thomas van LooyYemarshet Kelemework GebreyohannesAgnieszka WozniakJasmien CornillieJasmien WellensHaifu LiUlla VanleeuwGiuseppe FlorisMaria Debiec-RychterRaf SciotPatrick Schöffski Source Type: research

Gastrointestinal stromal tumour and other mesenchymal tumours of the gastrointestinal tract: the role of immunohistochemistry in an evolving era of molecular diagnostics
Significant progress has been made in the molecular characterization of soft tissue tumours arising in the gastrointestinal tract, primarily with the identification of recurrent translocations, gene amplifications and mutations in different tumour types. Translational studies have resulted in the development of many diagnostically useful immunohistochemical markers that reflect these underlying genetic changes. In addition, expression of some such markers is associated with distinctive clinical and histologic features, which may impart prognostic or predictive information, particularly for gastrointestinal stromal tumour.
Source: Diagnostic Histopathology - April 9, 2015 Category: Pathology Authors: Leona A. Doyle Tags: Immunohistochemistry as a surrogate to molecular diagnosis in gastrointestinal pathology Source Type: research

18F-FDG PET/CT in the evaluation of response to treatment adjustment in recurrence and or progression of gastrointestinal stromal tumours
CONCLUSION: This study demonstrates the potential role of 18F-FDG PET/CT scan as a valid consideration in the treatment response evaluation post treatment adjustment in recurrence and/or progression of GIST and may assist in early institution of new management or augmentation of ongoing treatment in this setting.
Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Nyakale, N., Harry, L., Ebrahim Dalais, T., Pillay, V. Tags: GI Non-Colorectal Posters Source Type: research

Molecular genetic features and risk assessment in a series of 30 patients who underwent an operation for gastrointestinal stormal tumours.
CONCLUSION: Molecular analysis data might have a role as a prognostic variable in models of risk assessment for patients with GISTs. PMID: 28240492 [PubMed - in process]
Source: South African Journal of Surgery - March 1, 2017 Category: Surgery Tags: S Afr J Surg Source Type: research

Is multivisceral resection in locally advanced gastrointestinal stromal tumours an acceptable strategy?
Conclusion MVR may be required to achieve negative margins in patients with large GISTs, and can be performed with acceptable morbidity and mortality.
Source: ANZ Journal of Surgery - May 24, 2016 Category: Surgery Authors: Jolene Si Min Wong, Grace Hwei Ching Tan, Richard Quek, Brian Kim Poh Goh, Li Lian Kwok, Mrinal Kumar, Khee Chee Soo, Melissa Ching Ching Teo Tags: Original Article Source Type: research

Genotype and risk of tumour rupture in gastrointestinal stromal tumour
ConclusionGastric GISTs with KIT exon 11 deletions involving codons 557 and 558 are at increased risk of tumour rupture. This high‐risk feature can be identified in the diagnostic evaluation and should be included in the assessment when neoadjuvant imatinib treatment is considered.
Source: British Journal of Surgery - January 17, 2018 Category: Surgery Authors: K. Boye, J. ‐M. Berner, I. Hompland, Ø. S. Bruland, S. Stoldt, K. Sundby Hall, B. Bjerkehagen, T. Hølmebakk Tags: Original article Source Type: research

P-023Gastrointestinal stromal tumours: Retrospective review of an institution
Introduction: Gastrointestinal stromal tumours (GIST) are rare tumours, accounting 1-3% of all gastrointestinal (GI) cancers. Our purpose was to review the experience of a single institution in advanced GIST, aiming on demographics, treatment and outcomes.
Source: Annals of Oncology - June 20, 2018 Category: Cancer & Oncology Source Type: research

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
AbstractGastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but the risk of relapse and progression to more advanced disease is substantial. Following the discovery of the molecular mechanisms underlying GISTs, targeted therapies for advanced GIST were developed, with the first being the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is recommended in international guidelines as first-line therapy to reduce the risk of GIST relapse in high-risk patients, and for locally advanced, inoperable and metastatic disease. Unfo...
Source: Gastric Cancer - March 13, 2023 Category: Gastroenterology Source Type: research

Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy.
CONCLUSION: A gastrointestinal stromal tumour metastastectomy surgical complexity score can predict morbidity, which may help in preoperative risk stratification and optimal treatment planning. PMID: 29579329 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - March 26, 2018 Category: Surgery Authors: Fairweather M, Cavnar MJ, Li GZ, Bertagnolli MM, DeMatteo RP, Raut CP Tags: Br J Surg Source Type: research

Refractory hypercalcaemia secondary to localised gastrointestinal stromal tumour.
We present a case of treatment-resistant hypercalcaemia in a patient with non-metastatic gastrointestinal stromal tumour, which resolved following excision of the tumour. PMID: 29658339 [PubMed - as supplied by publisher]
Source: Annals of the Royal College of Surgeons of England - April 16, 2018 Category: Surgery Authors: Hart T, Sinitsky D, Shamsiddinova A, Rohatgi A Tags: Ann R Coll Surg Engl Source Type: research

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate.
Authors: Zhou Y, Chen J, Weng X, Lin G, Huang Z, Shui H Abstract In the present study, imatinib mesylate (IM) was used to induce resistance in the gastrointestinal stromal tumour (GIST) cell line, GIST-T1, to establish a stable resistant cell line. The growth characteristics and expression profile of the established cell line were compared with those of the parental cell line. Additionally, the resistance mechanism of the gastrointestinal stromal tumours was preliminarily investigated. The GIST-T1 cells were cultured in vitro, and the drug was administered in the logarithmic phase of cell growth using intermittent ...
Source: Oncology Letters - May 11, 2018 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Seminar Gastrointestinal stromal tumour
Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in the abdomen. They can occur at any age, the median age being 60–65 years, and typically cause bleeding, anaemia, and pain. GISTs have variable malignant potential, ranging from small lesions with a benign behaviour to fatal sarcomas. Most tumours stain positively for the mast/stem cell growth factor receptor KIT and anoctamin 1 and harbour a kinase-activating mutation in either KIT or PDGFRA.
Source: LANCET - September 14, 2013 Category: Journals (General) Authors: Heikki Joensuu, Peter Hohenberger, Christopher L Corless Tags: Seminar Source Type: research

UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)
ConclusionsThe guidelines cover aetiology, genetics and underlying molecular mechanisms, diagnosis and initial investigations, staging and risk stratification, surgery, neoadjuvant and adjuvant therapy, the management of advanced disease and follow-up. The importance of mutational analysis in guiding treatment is highlighted, since this can indicate the most effective treatment and avoid administration of ineffective drugs, emphasising the need for management in specialist centres.
Source: Clinical Sarcoma Research - April 21, 2017 Category: Cancer & Oncology Source Type: research